PharOS
PharOS is a privately owned pharmaceutical company dedicated to developing, manufacturing, and supplying generics and value-added products globally. With a portfolio of over 104 products and nearly 9,880 marketing authorizations worldwide, PharOS aims to be first to market and last to exit, ensuring high-quality medicines are accessible in more than 116 countries.
Industries
Nr. of Employees
large (251-1000)
PharOS
Lesvou Str. (end), Thesi Loggos, Industrial Zone 144 52, Metamorfossi Attikis, Greece
Products
Bosentan
Cardiovascular agent presented as film-coated tablets; strengths: 62.5 mg, 125 mg. Regulatory status listed as DCP finalized; dossier format eCTD; stability data Zones I–IV; CPP available.
Zoledronic acid (concentrate for infusion)
Bisphosphonate presented as concentrate for solution for infusion; 4 mg/5 mL. Regulatory status DCP finalized; eCTD; stability Zones I–IV; CPP available.
Aripiprazole (orodispersible tablets)
Antipsychotic orodispersible tablets in 10 mg, 15 mg and 30 mg strengths. Regulatory status DCP finalized; eCTD; stability Zones I–IV; CPP available.
Abacavir / Lamivudine (600 mg / 300 mg)
Antiviral combination presented as film-coated tablets; 600 mg / 300 mg. Regulatory status DCP finalized; eCTD; stability Zones I–IV; CPP available.
Aripiprazole (tablets)
Antipsychotic film-coated tablets in 5 mg, 10 mg, 15 mg and 30 mg strengths. DCP finalized; eCTD; stability Zones I–IV; CPP available.
Capecitabine
Oncology agent as film-coated tablets; 150 mg, 500 mg. DCP finalized; eCTD; stability Zones I–IV; CPP available.
Bosentan
Cardiovascular agent presented as film-coated tablets; strengths: 62.5 mg, 125 mg. Regulatory status listed as DCP finalized; dossier format eCTD; stability data Zones I–IV; CPP available.
Zoledronic acid (concentrate for infusion)
Bisphosphonate presented as concentrate for solution for infusion; 4 mg/5 mL. Regulatory status DCP finalized; eCTD; stability Zones I–IV; CPP available.
Aripiprazole (orodispersible tablets)
Antipsychotic orodispersible tablets in 10 mg, 15 mg and 30 mg strengths. Regulatory status DCP finalized; eCTD; stability Zones I–IV; CPP available.
Abacavir / Lamivudine (600 mg / 300 mg)
Antiviral combination presented as film-coated tablets; 600 mg / 300 mg. Regulatory status DCP finalized; eCTD; stability Zones I–IV; CPP available.
Aripiprazole (tablets)
Antipsychotic film-coated tablets in 5 mg, 10 mg, 15 mg and 30 mg strengths. DCP finalized; eCTD; stability Zones I–IV; CPP available.
Capecitabine
Oncology agent as film-coated tablets; 150 mg, 500 mg. DCP finalized; eCTD; stability Zones I–IV; CPP available.
Services
Manufacture of pharmaceutical products on behalf of third parties across oral and parenteral dosage forms.
Compilation of eCTD-format dossiers and management of regulatory submissions including decentralized procedures.
Safety monitoring and pharmacovigilance support for marketed products.
Final product release activities including quality control testing and batch release processes.
Management of product distribution and supply chain logistics across multiple countries.
Formulation development for tablets, orodispersible forms, capsules and infusion concentrates from lab development to market-ready formulations.
Manufacture of pharmaceutical products on behalf of third parties across oral and parenteral dosage forms.
Compilation of eCTD-format dossiers and management of regulatory submissions including decentralized procedures.
Safety monitoring and pharmacovigilance support for marketed products.
Final product release activities including quality control testing and batch release processes.
Management of product distribution and supply chain logistics across multiple countries.
Formulation development for tablets, orodispersible forms, capsules and infusion concentrates from lab development to market-ready formulations.
Expertise Areas
- Product development
- Chemistry, Manufacturing & Controls (CMC)
- Regulatory affairs and dossier management
- Pharmacovigilance
Key Technologies
- Electronic Common Technical Document (eCTD)
- Decentralized regulatory procedure submissions (DCP)
- Stability testing across climatic zones I–IV
- Solid oral dosage formulation (film-coated, orodispersible, hard capsules)
News & Updates
PharOS sponsored the BotaniQ Student Team from Ekpaideftiki Anagennisi, which secured 6th place at the World Robot Olympiad 2024, highlighting the company's support for innovation and education.
PharOS organized a Blood Donation Day in 2020, emphasizing the importance of volunteering and blood donation during challenging times.
PharOS participated in the 19th Regulatory and Scientific Affairs Conference held in January 2020.
The company released its financial statement for 2015.
PharOS sponsored the BotaniQ Student Team from Ekpaideftiki Anagennisi, which secured 6th place at the World Robot Olympiad 2024, highlighting the company's support for innovation and education.
PharOS organized a Blood Donation Day in 2020, emphasizing the importance of volunteering and blood donation during challenging times.
PharOS participated in the 19th Regulatory and Scientific Affairs Conference held in January 2020.
The company released its financial statement for 2015.